IRCT20130812014333N182
Recruiting
Phase 2
The therapeutic efficiency and immunogenic assessments of the placenta mesenchymal stem cell–derived exosomes on alleviation of symptoms in patients with lupus (a clinical trials)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kermanshah University of Medical Sciences
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Class 3 or 4 resistant lupus nephritis
- •Parenchymal lung involvement or refractory heart involvement
- •Resistant vasculitis
- •Resistant CNS involvement
Exclusion Criteria
- •Other autoimmune diseases
- •Uncontrolled high blood pressure
- •Diabetes and other endocrine disorders
- •Cardiovascular failure
- •Severe renal failure and need to dialysis
- •Hepatic impairment
- •Endocarditis
- •Lupus pneumonia
- •Pregnancy and breast\-feeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Sub lingual immunotherapy of Nasal allergiesPerennial allergic rhinitis.Other allergic rhinitisIRCT2017042323235N9Vice chancellor for research, Mashhad University of Medical Sciences40
Recruiting
Phase 3
Evaluation of therapeutic effects of Crocina in knee osteoarthritisosteoarthritis.Primary osteoarthritis of other jointsM19.0IRCT20190419043318N1Bojnourd University of Medical Sciences60
Completed
Phase 1
Assessment of efficacy and safety of immunotherapy for unresectable locally advanced pancreatic cancer.pancreatic ductal carcinomaJPRN-UMIN000000769agoya University Hospital15
Completed
Phase 2
Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myelomaplasma cell myelomaJPRN-UMIN000009927Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University33
Completed
Not Applicable
To evaluate effect of immunotherapy .Health Condition 1: - Health Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxCTRI/2024/02/062655HCG NCHRI Cancer Centre10